Loading...
 

Volume 35, Issue 1, March 2024



Sign in to download the Issue in PDF format.

Back to the list
Mediterr J Rheumatol 2022;33(4):413-20
Article Links
Fever, Cutaneous Ulcers, and Arthritis Define the MDA5 Phenotype in Indian Patients with Idiopathic Inflammatory Myositis
Phanikumar Devarasetti, Irfan Mohammad, Anitha Desai, Liza Rajasekhar
Authors Information

Department of Clinical Immunology and Rheumatology, Nizam’s Institute of Medical Sciences, Hyderabad, Telangana, India

P Devarasetti, I Mohammad, L Rajasekhar

Keywords: MDA5 dermatomyositis, cutaneous ulcers, RPILD, CADM
References
  1. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975;292:344-7.
  2. Euwer RL, Sontheimer RD. Amyopathic dermatomyositis (dermatomyositissiné myositis). Presentation of six new cases and review of the literature. J Am Acad Dermatol 1991;24:959-66.
  3. Bendewald MJ, Wetter DA, Li X, Davis MD. Incidence of dermatomyositis and clinically amyopathic dermatomyositis: a population-based study in Olmsted County, Minnesota. Arch Dermatol 2010;146:26-30.
  4. Sato S, Hirakata M, Kuwana M, et al. Autoantibodies to 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum 2005;52:1571-6.
  5. Gupta L, Naveen R, Gaur P, Agarwal V, Aggarwal R. Myositis-specific and myositis-associated autoantibodies in a large Indian cohort of inflammatory myositis. Semin Arthritis Rheum 2021;51(1):113-20.
  6. Dunga SK, Kavadichanda C, Gupta L, Naveen R, Agarwal V, Negi VS. Disease characteristics and clinical outcomes of adults and children with anti-MDA-5 antibody-associated myositis: a prospective observational bicentric study. Rheumatol Int Epub 2021 May 29.
  7. Gupta L, Appani SK, Janardana R, Muhammed H, Lawrence A, Amin S, et al. Meeting report: MyoIN – Pan-India collaborative network for myositis research. Indian J Rheumatol 2019;14:136-42.
  8. Lundberg IE, Tjärnlund A, Bottai M, Werth VP, Pilkington C, Visser M, et al. 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis 2017 Dec;76(12):1955-64.
  9. Ghirardello A, Rampudda M, Ekholm L, Bassi N, Tarricone E, Zampieri S, et al. Diagnostic performance and validation of autoantibody testing in myositis by a commercial line blot assay. Rheumatology 2010 Dec 1;49(12):2370-74.
  10. Rajasekhar L, Shobha V, Anitha, Bhat V, Amin S, Misra R. Prevalence and Clinical Correlates of Myositis Specific Autoantibodies in Idiopathic Immune-Mediated Inflammatory Myositis - Results from a Multicentric Cohort (MyoIN) from India. JAPI 2021;69:36-40.
  11. Koga T, Fujikawa K, Horai Y, Okada A, Kawashiri SY, Iwamoto N, et al. The diagnostic utility of anti-melanoma differentiation-associated gene 5 antibody testing for predicting the prognosis of Japanese patients with DM. Rheumatology (Oxford) 2012 Jul;51(7):1278-84.
  12. Ceribelli A, Fredi M, Taraborelli M, Cavazzana I, Tincani A, Selmi C, et al. Prevalence and clinical significance of anti-MDA5 antibodies in European patients with polymyositis/dermatomyositis. Clin Exp Rheumatol 2014;32(6):891-7.
  13. Moghadam-Kia S, Oddis CV, Sato S, Kuwana M, Aggarwal R. Antimelanoma differentiation-associated gene 5 antibody: expanding the clinical spectrum in North American patients with dermatomyositis. J Rheumatol 2017;44:319-25.
  14. Narang NS, Casciola-Rosen L, Li S, Chung L, Fiorentino DF. Cutaneous ulceration in dermatomyositis: association with anti-melanoma differentiation-associated gene 5 antibodies and interstitial lung disease. Arthritis Care Res (Hoboken) 2015 May;67(5):667-72.
  15. Allenbach Y, Uzunhan Y, Toquet S, Leroux G, Gallay L, Marquet A, et al. Different phenotypes in dermatomyositis associated with anti-MDA5 antibody: Study of 121 cases. Neurology 2020;95(1):e70–8.
  16. Charbit L, Bursztejn AC, Mohamed S, Kaminsky P, Lerondeau B, Barbaud A, et al. [Extensive digital necrosis during dermatomyositis associated with MDA-5 antibodies]. Ann Dermatol Venereol 2016 Aug-Sep;143(8-9):537-42 [Article in French].
  17. Fiorentino D, Chung L, Zwerner J, Rosen A, Casciola-Rosen L. The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study. J Am AcadDermatol 2011;65:25-34.
  18. Wong VT, So H, Lam TT, Yip RM. Myositis-specific autoantibodies and their clinical associations in idiopathic inflammatory myopathies. Acta Neurol Scand 2021 Feb;143(2):131-9.
  19. Hall JC, Casciola-Rosen L, Samedy L-A, Werner J, Owoyemi K, Danoff SK, et al. Anti-melanoma differentiation associated protein 5–associated dermatomyositis: expanding the clinical spectrum. Arthritis Care Res 2013;65:1307-15.
  20. Labrador-Horrillo M, Martinez MA, Selva-O'Callaghan A, Trallero-Araguas E, Balada E, Vilardell-Tarres M, et al. Anti-MDA5 antibodies in a large Mediterranean population of adults with dermatomyositis. J Immunol Res 2014;2014:290797.
  21. Motegi SI, Sekiguchi A, Toki S, Kishi C, Endo Y, Yasuda M, et al. Clinical features and poor prognostic factors of anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis with rapid progressive interstitial lung disease. Eur J Dermatol 2019 Oct 1;29(5):511-7.
  22. Yamaguchi K, Yamaguchi A, Itai M, Kashiwagi C, Takehara K, Aoki S, et al. Clinical features of patients with anti-melanoma differentiation-associated gene-5 antibody-positive dermatomyositis complicated by spontaneous pneumomediastinum. Clin Rheumatol 2019 Dec;38(12):3443-50.
  23. Tansley SL, Betteridge ZE, Gunawardena H, Jacques TS, Owens CM, Pilkington C, et al. UK Juvenile Dermatomyositis Research Group. Anti-MDA5 autoantibodies in juvenile dermatomyositis identify a distinct clinical phenotype: a prospective cohort study. Arthritis Res Ther 2014 Jul 2;16(4):R138.
  24. Sag E, Demir S, Bilginer Y, Talim B, Haliloglu G, Topaloglu H, Ozen S. Clinical features, muscle biopsy scores, myositis specific antibody profiles and outcome in juvenile dermatomyositis. Semin Arthritis Rheum 2021 Feb;51(1):95-100.
  25. Melki I, Devilliers H, Gitiaux C, Bondet V, Duffy D, Charuel JL, et al. Anti-MDA5 juvenile idiopathic inflammatory myopathy: a specific subgroup defined by differentially enhanced interferon-α signalling. Rheumatology (Oxford) 2020 Aug 1;59(8):1927-37.
  26. Li DM, Wang L, Liu MY, Xu L, Tang XM. [The analysis of clinical phenotypes and autoantibodies in juvenile dermatomyositis]. Zhonghua Er Ke Za Zhi 2020 Dec 2;58(12):966-972 [Article in Chinese].
  27. Horn S, Minden K, Speth F, Dressler F, Grösch N, Haas JP, et al. Myositis-specific autoantibodies and their associated phenotypes in juvenile dermatomyositis: data from a German cohort. Clin Exp Rheumatol Epub 2020 Oct 29.
  28. Mamyrova G, Kishi T, Shi M, Targoff IN, Huber AM, Curiel RV, et al. Childhood Myositis Heterogeneity Collaborative Study Group. Anti-MDA5 autoantibodies associated with juvenile dermatomyositis constitute a distinct phenotype in North America. Rheumatology (Oxford) 2021 Apr 6;60(4):1839-49.
  29. Kobayashi N, Takezaki S, Kobayashi I, Iwata N, Mori M, Nagai K, et al. Clinical and laboratory features of fatal rapidly progressive interstitial lung disease associated with juvenile dermatomyositis. Rheumatology 2015;54:784-91.
  30. Li ZY, Gill E, Mo F, Reyes C. Double anti-PL-7 and anti-MDA-5 positive Amyopathic Dermatomyositis with rapidly progressive interstitial lung disease in a Hispanic patient. BMC Pulm Med 2020 Aug 15;20(1):220.
  31.  Naniwa T, Tamechika S, Okazaki Y, Maeda S, Kuwana M. Coexistence of anti-melanoma differentiation-associated gene 5 and anti-aminoacyl-transfer RNA synthetase antibodies in a patient with dermatomyositis and rapidly progressive and relapsing interstitial lung disease. Mod Rheumatol Case Rep 2017;1(1):3-8.
  32. Xing X, Li A, Li C. Anti-Ro52 antibody is an independent risk factor for interstitial lung disease in dermatomyositis. Respir Med 2020 Oct;172:106134.
  33. Xu A, Ye Y, Fu Q, Lian X, Chen S, Guo Q, et al. Prognostic values of anti-Ro52 antibodies in anti-MDA5-positive clinically amyopathic dermatomyositis associated with interstitial lung disease. Rheumatology (Oxford) 2020 Dec 17:keaa786.
  34. Mehta P, Agarwal V, Gupta L. High early mortality in idiopathic inflammatory myopathies: results from the inception cohort at a tertiary care centre in northern India. Rheumatology 2021;keab001.